Technical Analysis for TARS - Tarsus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 32.04 | -0.53% | -0.17 |
TARS closed down 0.53 percent on Friday, April 26, 2024, on 54 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Spinning Top | Other | -0.53% | |
| NR7 | Range Contraction | -0.53% | |
| BB Squeeze Ended | Range Expansion | -0.53% | |
| Gapped Down | Weakness | -0.53% | |
| Lower Bollinger Band Touch | Weakness | -0.53% | |
| Oversold Stochastic | Weakness | -0.53% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | 1 day ago |
| 10 DMA Resistance | 1 day ago |
| Outside Day | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 2 % | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.4 |
| 52 Week Low | 12.66 |
| Average Volume | 699,739 |
| 200-Day Moving Average | 22.65 |
| 50-Day Moving Average | 33.92 |
| 20-Day Moving Average | 34.57 |
| 10-Day Moving Average | 33.26 |
| Average True Range | 1.86 |
| RSI (14) | 42.20 |
| ADX | 18.03 |
| +DI | 19.57 |
| -DI | 17.90 |
| Chandelier Exit (Long, 3 ATRs) | 32.87 |
| Chandelier Exit (Short, 3 ATRs) | 36.85 |
| Upper Bollinger Bands | 37.88 |
| Lower Bollinger Band | 31.26 |
| Percent B (%b) | 0.12 |
| BandWidth | 19.17 |
| MACD Line | -0.36 |
| MACD Signal Line | 0.11 |
| MACD Histogram | -0.4634 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.97 | ||||
| Resistance 3 (R3) | 35.03 | 34.12 | 34.48 | ||
| Resistance 2 (R2) | 34.12 | 33.38 | 34.09 | 34.31 | |
| Resistance 1 (R1) | 33.08 | 32.91 | 32.63 | 33.02 | 34.15 |
| Pivot Point | 32.17 | 32.17 | 31.94 | 32.14 | 32.17 |
| Support 1 (S1) | 31.13 | 31.43 | 30.68 | 31.07 | 29.93 |
| Support 2 (S2) | 30.22 | 30.96 | 30.19 | 29.77 | |
| Support 3 (S3) | 29.18 | 30.22 | 29.60 | ||
| Support 4 (S4) | 29.12 |
